Argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Argenx has reported its full year 2023 financial results and provided an update on its business for the fourth quarter. The company generated $1.2 billion in global net product sales for the full year, which represents a significant increase compared to the previous year. In the fourth quarter alone, Argenx recorded $374 million in net product sales.

One of the key highlights for Argenx in 2023 was the acceptance of sBLA for VYVGART® Hytrulo for CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) by the FDA with a PDUFA target action date of June 21, 2024. This is a significant milestone for the company as it brings them one step closer to bringing this important treatment option to patients in need.

In addition to this, Argenx is on track to report data from six Phase 2 proof-of-concept trials by the end of 2024. This includes trials for potential treatments for multiple sclerosis, autoimmune disorders, and other conditions. These trials are an important part of Argenx's ongoing research and development efforts, and they have the potential to lead to new treatment options for patients.

Argenx will be hosting a conference call today at 230 pm CET to discuss its full year 2023 financial results and provide an update on its business. This is an opportunity for investors and stakeholders to learn more about the company's performance and future plans.